Tildrakizumab
Metastatic Castration Resistant Prostate Cancer
Institute of Cancer Research, United Kingdommonoclonal_antibodyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Metastatic Castration Resistant Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enzalutamide Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BBB |
Abiraterone Acetate Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | BBB |
PREDNISONE TABLETS Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | BB |
177lu-psma Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 | BB |
Docetaxel National Cancer Institute (NCI) | Phase 3 | BB |
View all 39 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →